advisorsecurities master

GRIGRI Bio, Inc. Common Stock

CSNasdaq (XNAS)·USD

Identity

Security key
16219
Ticker
GRI
Type
CSCommon Stock
Exchange
Nasdaq(XNAS)
Venue group
NASDAQ
Operating MIC
XNAS
Market
stocks
Locale
us
Currency
USD
Listed
2023-04-24
Round lot
100
Active
Yes
Last seen in a load
2026-08-14 20:49
Vendor updated
2026-08-13 06:09
Ticker root / suffix
GRI

Detail

Enriched 2026-08-14 20:47

Market cap
$3,453,134.1
Shares outstanding (class)
1,770,838
Shares outstanding (weighted)
1,770,838
SIC
2834 PHARMACEUTICAL PREPARATIONS
Employees
5
Location
LA JOLLA, CA
Description

GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.

Market cap and share counts drift.

Funds holding this security

Identifiers

Classification

Fund data